Reference number 2018-04657
Coordinator NANEXA AB
Funding from Vinnova SEK 500 000
Project duration December 2018 - July 2019
Status Ongoing

Purpose and goal

The goal of this project is to develop a drug formulation which improves the treatment that combats the progression of acute myeloid leukaemia (AML) and reduces severity of its side effects. AML, the most common type of aggressive leukaemia in adults, leads to disproportionately high morbidity in patients, and impacts the economy through high mortality rates and hospitalisation costs. The available treatment options are highly ineffective for the elderly and pose a significant challenge globally.

Expected results and effects

Nanexa aims to address this challenge by developing a novel generic drug to improve patients’ life expectancy. Nanexa’s programme is based on a drug delivery system generated with a verified Atomic Layer Deposition technology and proves markedly effective in controlling drug plasma concentration in in vivo studies. This therapy will improve intervention outcomes for patients, improve administration scheme, and lower additional treatment and healthcare costs of prolonged hospitalisation.

Planned approach and implementation

As a part of this SME Phase 1 feasibility testing, Nanexa wants to: Perform market feasibility study to estimate the potential of PharmaShell® for improved AML treatment, including out-licensing scenarios to large-, and mid-size pharmaceutical companies, Prepare detailed project plans and budget for the pre-clinical studies and the Phase I clinical trial, Assess clinical strategies: collaboration with local hospitals and CROs.

The project description has been provided by the project members themselves and the text has not been examined by our editors.